Chinese biotech Rezubio has announced the initiation of a Phase 1 PK/PD study of RZ-520, which Rezubio describes as “a novel inhaled therapeutic drug candidate for the treatment of chronic respiratory diseases.” According to Rezubio, both the US FDA and the NMPA cleared INDs for the study.
RZ-520, which is based on the company’s membrane-anchored drug design (MADD) platform, has “demonstrated robust therapeutic efficacy across multiple disease models, with superior safety and negligible systemic drug exposure” in preclinical trials, Rezubio says. The company is also developing a therapy for the treatment of obesity based on the MADD platform.
Rezubio CEO Yusheng Xiong commented, “The dual IND clearances from the FDA and NMPA and first cohort dosing of RZ-520 mark a pivotal milestone for both this program and our MADD platform. Advancing our second MADD-derived drug candidate into clinical development further validates the power of our platform to design tissue-targeted therapies that address a broad spectrum of challenging diseases. We look forward to advancing these clinical studies and evaluating RZ-520’s potential to deliver a transformative and highly differentiated treatment option for patients living with chronic respiratory diseases.”
Read the Rezubio press release
